C3 glomerulonephritis in a patient treated with anti–PD-1 antibody - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue European Journal of Cancer Année : 2020

C3 glomerulonephritis in a patient treated with anti–PD-1 antibody

Résumé

Immune checkpoint inhibitors (ICIs) have dramati-cally transformed the treatment of solid tumors. ICIsinduce an immune response against tumoral cells as aresult of the removal of T-cell inhibition [1]. The logicalcounterpart of turning off T-cell inhibitory mechanismsis the onset of immune-related adverse events (irAEs)that affect different organs. Although the most frequentrenal irAE is acute interstitial nephritis [2], we report afirst case of C3 glomerulonephritis (GN) associated withthe use of an antieProgrammed Cell Death 1 (PD-1)humanised antibody.
Fichier non déposé

Dates et versions

inserm-02449014 , version 1 (22-01-2020)

Identifiants

Citer

Simon Ville, Christine Kandel-Aznar, Veronique Fremeaux-Bacchi, Fadi Fakhouri. C3 glomerulonephritis in a patient treated with anti–PD-1 antibody. European Journal of Cancer, 2020, 125, pp.46-48. ⟨10.1016/j.ejca.2019.11.011⟩. ⟨inserm-02449014⟩
21 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More